Andrew J. Norton

Mitoxantrone is superior to doxorubicin in a multiagent weekly regimen for patients older than 60 with high-grade lymphoma: results of a BNLI randomized trial of PAdriaCEBO versus PMitCEBO.

K. Maclennan, W. Gregory, P. Hoskin, 2001, Blood.